Is there a role for menopausal hormone therapy (MHT) for cardiovascular disease prevention in select postmenopausal women?

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 6, 2013, Pages 722-734

  Cutchins, Alexis ^a   Wenger, Nanette K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Estrogen; Hormones; Menopausal hormone therapy; Myocardial infarction; Stroke

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLIMACTERIUM; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; ELDERLY CARE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; TREATMENT REFUSAL; VENOUS THROMBOEMBOLISM;

EID: 84890572000     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-013-0256-3     Document Type: Review

References (24)

1. Moyer VA, Force USPST. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158(1):47-54. doi: 10.7326/0003-4819-158-1-201301010-00553. [published Online First: Epub Date]. Reviewed the pertinant randomized controlled trials evaluating MHT and primary prevention of chronic diseases and recommended not using MHT for primary prevention of cardiovascular disease.
2. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women - 2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-62. doi: 10.1161/CIR.0b013e31820faaf8. published Online First: Epub Date.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
4. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-12. doi: 10.1001/jama.291.14.1701. published Online First: Epub Date.
5. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239. doi: 10.1136/bmj.39266.425069.AD. published Online First: Epub Date.
6. Toh S, Hernandez-Diaz S, Logan R, Rossouw JE, Hernan MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med. 2010;152(4):211-7. doi: 10.1059/0003-4819-152-4-201002160-00005. published Online First: Epub Date.
7. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77. doi: 10.1001/jama.297.13.1465. published Online First: Epub Date.
8. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305-14. doi: 10.1001/jama.2011.382. published Online First: Epub Date. A subset analysis of WHI, examining the effects of unopposed estrogen on recently menopausal women. These women displayed a reduced risk for coronary heart disease.
9. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166(3):357-65. doi: 10.1001/archinte.166.3.357. published Online First: Epub Date.
10. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. doi: 10.1136/bmj.e6409. published Online First: Epub Date. This randomized trial seeks to establish the effects of MHT in recently menopausal women on primary cardiovascular disease prevention. They demonstrated a reduction in the primary composite endpoint of death, MI, and heart failure with use of MHT for 10 years. Limitations of this study include a paucity of cardiovascular incidents, lack of placebo, and study design for evaluation of osteoporosis, not cardiovascular disease outcomes.
11. Su IH, Chen YC, Hwang WT, et al. Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women. Menopause. 2012;19(8):931-41. doi: 10.1097/gme.0b013e31824362ff. published Online First: Epub Date.
12. Miller VM, Black DM, Brinton EA, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2009;2(3):228-39. doi: 10.1007/s12265-009-9104-y. published Online First: Epub Date.
13. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44(3):671-719. doi: 10.1016/j.jacc.2004.07. 002. published Online First: Epub Date.
14. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148-304. doi: 10.1161/CIRCULATIONAHA.107.181940. published Online First: Epub Date.
15. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(23):e652-735. doi: 10.1161/CIR. 0b013e31823c074e. published Online First: Epub Date.
16. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-13.
17. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49-57.
18. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol. 2002;109(9):1056-62.
19. Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 2001;104(19):2300-4.
20. Tackett AH, Bailey AL, Foody JM, et al. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. Am Heart J. 2010;160(4):678-84. doi: 10.1016/j.ahj.2010. 06.030. published Online First: Epub Date.
21. Bretler DM, Hansen PR, Sorensen R, et al. Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study. BMJ. 2012;344:e1802. doi: 10.1136/bmj.e1802. published Online First: Epub Date. A retrospective cohort study supporting no increased risk of reinfarction or death from cardiovascular disease in the first year post MI in those women who continue MHT.
22. de Lauzon-Guillain B, Fournier A, Fabre A, et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l'Education Nationale (E3N) cohort. Diabetologia. 2009;52(10):2092-100. doi: 10.1007/s00125-009-1456-y. published Online First: Epub Date.
23. Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008;29(21):2660-8. doi: 10.1093/eurheartj/ehn408. published Online First: Epub Date.
24. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519. doi: 10.1136/bmj.c2519. published Online First: Epub Date.